novartis glp-1 receptor agonist weight management diabetes treatments loss with medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine GLP-1 Receptor Agonists as Treatments

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two gut hormones, defined incretins, responsible for the amplification of insulin secretion after oral glucose intake

Rapid weight loss with GLP1 receptor agonists can come at the cost of skeletal muscle, potentially undermining metabolic and functional outcomes

These statements have not been evaluated by the Food and Drug Administration

While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives

GLP-1 Data Survey 2025: GLP-1 Weight Loss, Types of GLP-1 Used, GLP-1 Duration Usage, GLP-1 Side Effects, Satisfaction & more.

- **Curb appetite:** Helping individuals feel full, potentially leading to reduced food intake